NeuroMetrix — IPO Roadshow (November 2016)
22 slides from NeuroMetrix's IPO roadshow presentation, Nov 23, 2016
Slide 1: NeuroMetrix Free Writing Prospectus, December 2016
Nasdaq : NURO Shai N. Gozani, MD, PhD Tom Higgins President & CEO Chief Financial Officer December 2016 ISSUER FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration Statement No. 333 - 207566 Dated November 23, 2016
Slide 2: Free Writing Prospectus
2 Free Writing Prospectus NeuroMetrix , Inc. is providing this presentation which highlights basic information about the Company and the offering to which this communication relates. Because it is a summary, it does not contain all the information that should be considered before investing in our se
Slide 3: Safe Harbor Statement
Safe Harbor Statement The statements contained in this corporate presentation include forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including, without
Slide 4: Equity Offering Overview
Equity Offering Overview • Issuer: • Exchange: • Offering Size • Securities Offered • Use of Proceeds: • Placement Agent: • NeuroMetrix , Inc • Nasdaq: NURO • $30.0 million • Class A Units – one share of common stock and a warrant to purchase one share of common stock at an exercise price of 110% of
Slide 5: Overview
Overview • Boston based healthcare company • Founded in 1996 as spin - off from MIT • Integrate bioelectrical and digital medicine to address chronic disease • Industry leading R&D capabilities • Experienced commercialization team • Market a first - in - class over - the - counter wearable device to
Slide 6: Commercial Product Portfolio
Commercial Product Portfolio Deep Technology & Market Foundation 6 Neuro - Diagnostics Neuro - Therapeutics ADVANCE™ Launched 2008 Winding down (orthopedics, diabetes) DPNCheck ® Launched 2012 (diabetes) SENSUS® Launched 2013 Winding down (chronic pain) Quell® Launched 2015 (chronic pain) Quell 59%
Slide 7: Chronic Pain Market: Large Opportunity with Many Unmet Needs
Chronic Pain Market Large Opportunity with Many Unmet Needs • 100M US adults, 1.5B worldwide – Low back pain, arthritis, diabetic nerve pain, fibromyalgia, cancer, CRPS, PHN, neck pain, facial pain • $600B annual cost in US 1 • $35B global market 2 • $20B annual out - of - pocket spending in US 3 •
Slide 8: Quell TV Commercial
Quell TV Commercial 8 NeuroMetrix, Inc. ©2016
Slide 9: Quell Wearable Pain Relief Technology
Quell Wearable Pain Relief Technology Widespread Chronic Pain Relief without Side Effects • High - power wearable neurostimulator • Fully automated intelligent stimulation control • Integrated digital health monitoring • Connected device • Rechargeable Lithium - Polymer (3 - 7 days) • Class II medic
Slide 10: Mobile and Digital Medicine Strategy
10 Mobile and Digital Medicine Strategy Enhance User Experience • iOS and Android apps • Quell app enhances user experience – Interactive therapy dashboard – Real - time control of device – Customize device settings – Therapy, sleep, activity, and pain monitoring – Electrode management & purchasing
Slide 11: Quell Business Model
Quell Business Model Devices Create Recurring Revenue Stream Electrodes: $29.95 (2 per package) Recurring Revenue Revenue Per User Every Three Months Every Month Year 1 $370 $610 Year 2+ $120 $360 Reorder Rate Starter Kit: $249 (device, 1 electrode package, sports band) 11 NeuroMetrix, Inc. ©2016
Slide 12: Market Opportunity of 19M Chronic Pain Sufferers
Market Opportunity of 19M Chronic Pain Sufferers 12 100M 19M Note. Market opportunity estimate independently developed by Connelly Partners (Boston, MA) using Nielsen MRI data. 2016. • Not migraine or headache • 40+ years of age • $75K+ household income • College educated • Active • Want to minimize
Slide 13: North America Quell Distribution
North America Quell Distribution 13 Consumer Professional e - commerce Retail (1500 stores) TV QuellRelief.com Chiro /PT Direct WBC Group NeuroMetrix, Inc. ©2016 Physicians Institutional (VA)
Slide 14: Quell Demonstrating Consistent Growth
Quell Demonstrating Consistent Growth 14 NeuroMetrix, Inc. ©2016 $602 $985 $1,478 $1,703 $2,534 $2,900 0 500 1000 1500 2000 2500 3000 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Invoiced Sales GAAP Revenue Deferred Revenue Sales & Revenue ($1000s) 2,607 4,514 6,675 8,138 11,201 12,086 0 2000 400
Slide 15: Consumers Report Positive Experience With Quell
Consumers Report Positive Experience With Quell 15 NeuroMetrix, Inc. ©2016 1 2 3 4 5 >100 Reviews <100 Reviews Expected 2 Note 1. Tabulated August 27, 2016 Note 2. Expected average rating based on clinical efficacy and return rate (75% with 4 or 5 stars and 25% with 1 or 2 stars). Average Customer S
Slide 16: Quell Provides Therapeutic Benefit to ~80% of Subjects
Quell Provides Therapeutic Benefit to 70 - 80% of Subjects • 81% of subjects reported improvement in chronic pain • 67% of subjects reported reduction in pain medication use 16 NeuroMetrix, Inc. ©2016 Gozani. Fixed - Site High - Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of
Slide 17: Quell has a Strong Competitive Position
Quell has a Strong Competitive Position Benefits Quell ® OTC TENS 1 OTC Internal Analgesics 2 OTC External Analgesics 3 Non - narcotic Pain Meds 4 Opioid Pain Meds 5 Treats Chronic Pain +/ - +/ - +/ - Multi - Site Pain Relief Nighttime Pain Relief No Major Side Effects No Addiction Potential Smartph
Slide 18: Intellectual Property
Intellectual Property • 45 issued U.S. patents • 3 issued foreign patents • 34 pending patent applications – 17 U.S. applications – 17 foreign national applications • Wearable therapeutic technology (Quell) – 2 issued utility patents (US 8,948,876 and US 9,474,898) – 3 issued design patents – 30 pen
Slide 19: Growth Strategy
Growth Strategy • Expand retail distribution – Build on presence in pharmacy (CVS, Walgreens) and mass merchandisers (Target) – Move into new retail categories (electronics, club) • Product innovation – Aggressive product road - map, next product launch at CES 2017 – Decrease COGS, improve usability
Slide 20: Financials
Financials 20 NeuroMetrix , Inc. ©2016 Outstanding 5,318,273 Preferred, as-converted 10,892,929 16,211,202 Recent Closing Price $1.27 Market Value $20,588,227 Market Valuation (Nov 21, 2016) ($000's) Q3 2016 Q2 2016 Q1 2016 2015 2014 2013 Revenue $3,389 $2,647 $2,275 $7,300 $5,513 $5,279 - Quell $2,
Slide 21: Management Team
Shai N. Gozani, MD., PhD. President, CEO and Founder Thomas T. Higgins SVP and CFO Frank McGillin SVP and General Manager, Consumer Management Team 21 NeuroMetrix, Inc. ©2016 • Extensive public company CFO experience • Strong operational background • 20+ years consumer health care experience • Deep
Slide 22: Investment Highlights
Investment Highlights • Commercial stage healthcare company combining bioelectrical and digital medicine to address chronic disease • Market a first - in - class over - the - counter wearable device to treat chronic pain • Razor/razor - blade business model with good sales growth in first 6 quarters